共 226 条
[1]
Neri E(2016)ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents Eur Radiol 26 921-931
[2]
Bali MA(2014)CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects Radiology 272 635-654
[3]
Ba-Ssalamah A(2015)Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis Radiology 275 97-109
[4]
Boraschi P(1995)Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging Radiology 195 785-792
[5]
Brancatelli G(2000)Dynamic MR imaging of liver metastases with Gd-EOB-DTPA Acta Radiol 41 255-262
[6]
Alves FC(2012)Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients Eur Radiol 22 171-180
[7]
Grazioli L(2010)Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma Radiology 255 459-466
[8]
Helmberger T(2010)Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging Radiology 256 151-158
[9]
Lee JM(2013)Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma Abdom Imaging 38 793-801
[10]
Manfredi R(2017)Primary hepatic neuroendocrine tumors: multi-modal imaging features with pathological correlations Cancer Imaging 17 20-798